These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19249905)

  • 1. The role of renin-angiotensin system in prothrombotic state in essential hypertension.
    Remková A; Remko M
    Physiol Res; 2010; 59(1):13-23. PubMed ID: 19249905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.
    Remková A; Kratochvíl'ová H; Durina J
    J Hum Hypertens; 2008 May; 22(5):338-45. PubMed ID: 18305548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin inhibition: a new modality for hypertension management.
    Siragy HM
    Curr Hypertens Rep; 2007 Aug; 9(4):291-4. PubMed ID: 17686379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin system blocking drugs.
    Robles NR; Cerezo I; Hernandez-Gallego R
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular smooth muscle cells are responsible for a prothrombotic phenotype of spontaneously hypertensive rat arteries.
    Ait Aissa K; Lagrange J; Mohamadi A; Louis H; Houppert B; Challande P; Wahl D; Lacolley P; Regnault V
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):930-7. PubMed ID: 25722431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system.
    Becher UM; Endtmann C; Tiyerili V; Nickenig G; Werner N
    Curr Hypertens Rep; 2011 Feb; 13(1):86-92. PubMed ID: 21108024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
    Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS inhibitors' dose-dependent efficacy: myth or reality?
    Taddei S
    Curr Med Res Opin; 2015; 31(7):1245-56. PubMed ID: 25985327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
    Scott BB; McGeehan GM; Harrison RK
    Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.